Impact of international guidelines on the management of cardiovascular risk factors in diabetic patients with peripheral arterial disease

International Angiology

Volumn 28, Issue 3, 2009, Pages 175-180

  Margeta, C ^a   Giurgea, A ^a   Hammer, A ^a   Schlager, O ^a   Zehetmayer, S ^a   Koppensteiner, R ^a   Willfort Ehringer, A ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cardiovascular diseases; Diabetes mellitus; Hydroxymethylglutaryl CoA reductase inhibitors; Lipids; Risk factors

Indexed keywords

ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; LIPID;

ADULT; AGED; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DIABETIC PATIENT; ECHOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INTERNATIONAL COOPERATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; TRIACYLGLYCEROL BLOOD LEVEL; AMBULATORY CARE; ANKLE BRACHIAL INDEX; ARTERIAL OCCLUSIVE DISEASES; AUSTRIA; BLOOD; BODY MASS; CARDIOVASCULAR DISEASES; CLINICAL PRACTICE; COMPLICATION; DIABETIC ANGIOPATHIES; DYSLIPIDEMIAS; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; TREATMENT OUTCOME; WAIST CIRCUMFERENCE;

AGED; AMBULATORY CARE; ANKLE BRACHIAL INDEX; ARTERIAL OCCLUSIVE DISEASES; AUSTRIA; BLOOD GLUCOSE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; DIABETIC ANGIOPATHIES; DYSLIPIDEMIAS; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION; TREATMENT OUTCOME; WAIST CIRCUMFERENCE;

EID: 69549118185     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Criqui MH, Fronek A, Barett-Connor E, Barrett-Connor E, Gabriel S. The prevalence of peripheral arterial disease in a defined population. Circulation 1985;71:510-551 (Pubitemid 15133809)
2. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis VALLEY Diabetes Study. Circulation 1995;91:1472-1479
3. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004;110:738-743 (Pubitemid 39056275)
4. Diehm C, Schuster A, Allenberg JR, Darius H, Haberl R, Lange S et al. High prevalence of peripheral arterial disease and co-morbidity in 6880primary care patients: cross-sectional study. Atherosclerosis 2004;172:95-105. (Pubitemid 38058606)
5. Fowkes FG, Housley E, Riemersma RA, Macintyre CC, Cawood EH, Prescott RJ et al. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh artery Study. Am J Epidemiol 1992;135:331-340
6. Willingendael EM, Teijink JA, Bartelink ML, Kuiken BW, Boiten J, Moll FL et al. Influence of smoking on incidence and prevalence of peripheral arterial disease. J Vasc Surg 2004;40:1158-1165 (Pubitemid 40037284)
7. Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication: a risk profile from the Framingham heart study. Circulation 1997;96:44-49 (Pubitemid 27298402)
8. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda y, Mas JL et al. REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180-189
9. HPSCG.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial Lancet 2002;360:7-22.
10. EUROSPIRE: A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J 1997;18:1569-1582
11. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Eur Heart J 2001;22:554-572
12. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group. Inter-Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007;33:1-75. (Pubitemid 46068992)
13. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-969 (Pubitemid 30681627)
14. Alberti KG, Zimmer PZ. Definition, diagnosis and classification of diabetes mellitus provisional report of WHO classification. Diabet Med 1998b;15:539-553
15. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999;17:151-183
16. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998,339:229-234 (Pubitemid 28350165)
17. Miettinen H, Lehto S, Salomaa V, Mähönen M, Niemelä M, Haffner SM et al. Impact of diabetes on mortality after the first myocardial infarction: the FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998;21:69-75.
18. Fonarow GC, French WJ, Parsons LS, Sun H, Malmgren JA. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation 2001;103:38-44. (Pubitemid 32050433)
19. Sueta CA, Chowdhury M, Boccuzzi SJ, Smith SC Jr, Alexander CM, Londhe A et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999;83:1303-1307 (Pubitemid 29205736)
20. Shepard J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006;29:1220-1226 (Pubitemid 44125913)
21. Andrews TC, Ballantyne CM, Hsia JA, Kramer JH. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 2001;111:185-191
22. Brown AS, Bakker-Arkema RG, Yellen L, Henley RW Jr, Guthrie R, Campbell CF et al. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and Simvastatin. J Am Coll Cardiol 1998;32:665-672 (Pubitemid 28435251)
23. Hunninghake D, Bakker-Arkema RG, Wigand JP, Drehobl M, Schrott H, Early JL et al. Treating to meet NCEP-recommended LDL cholesterol concentrations with Atorvastatin, Fluvastatin, lovastatin, or Simvastatin in patients with risk factors for coronary heart disease. J Fam Pract 1998;47:349-356 (Pubitemid 28541566)